Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Italian Real Life Experience with Brentuximab Vedotin: Results of a National Observational Study on Relapsed/Refractory Hodgkin's Lymphoma

Blood (2016) 128 (22): 4161.

https://doi.org/10.1182/blood.V128.22.4161.4161

Published: 2016

Journal Articles

Italian Real Life Experience with Brentuximab Vedotin: Results of a National Observational Study on Relapsed/Refractory Anaplastic Large Cell Lymphoma

Blood (2016) 128 (22): 3007.

https://doi.org/10.1182/blood.V128.22.3007.3007

Published: 2016

Journal Articles

The Combination of Weekly Infusion of Rituximab and Bortezomib Is Effective in Relapsed or Refractory Indolent and Mantle Cell Lymphoma: Long-Term Results of Phase II BRIL06 Study of the Fondazione Italiana Linfomi (FIL)

Blood (2015) 126 (23): 2735.

https://doi.org/10.1182/blood.V126.23.2735.2735

Published: 2015

Journal Articles

High Cure Rates of the Short-Term GITIL Chemotherapy Programme for Adult Patients with Burkitt Lymphoma

Jacopo Mariotti, MD, Anna Guidetti, MD, Michele Magni, MD, Paola Matteucci, MD, Liliana Devizzi, MD, Andrés J.M. Ferreri, Paolo Corradini, MD, Anna Dodero, MD, Amalia De Renzo, Alessandro Massimo Gianni, MD, Massimo Di Nicola, MD

Blood (2014) 124 (21): 1734.

https://doi.org/10.1182/blood.V124.21.1734.1734

Published: 2014

Journal Articles

Impact Of Bone Marrow Involvement On Outcome Of Young Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL) Treated In The Phase III Randomized Trial (DLCL04) With Rituximab Dose-Dense Chemotherapy Followed By Intensified High-Dose Chemotherapy and Autologous Stem Cell Transplantation (HDC+ASCT) Or Standard Rituximab Dose Dense Chemotherapy: A Study of The Fondazione Italiana Linfomi (FIL)

Blood (2013) 122 (21): 4340.

https://doi.org/10.1182/blood.V122.21.4340.4340

Published: 2013

Journal Articles

Role Of Interim,-PET In Poor Prognosis Young Patients With Diffuse Large B Cell Lymphoma At Diagnosis: Data From An Ancillary Study Of a Prospective Randomized Phase III Study (DLCL04) From the Fondazione Italiana Linfomi

Blood (2013) 122 (21): 5088.

https://doi.org/10.1182/blood.V122.21.5088.5088

Published: 2013

Journal Articles

Rituximab Dose-Dense Chemotherapy Followed by Intensified High-Dose Chemotherapy and Autologous Stem Cell Transplantation (HDC+ASCT) Significantly Reduces the Risk of Progression Compared to Standard Rituximab Dose-Dense Chemotherapy As First Line Treatment in Young Patients with High-Risk (aa-IPI 2–3) Diffuse Large B-Cell Lymphoma (DLBCL): Final Results of Phase III Randomized Trial DLCL04 of the Fondazione Italiana Linfomi (FIL)

Blood (2012) 120 (21): 688.

https://doi.org/10.1182/blood.V120.21.688.688

Published: 2012

Journal Articles

Brief Chemoimmunotherapy R-FND with Rituximab Consolidation Followed by Randomization Between Rituximab Maintenance Vs. Observation As First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Final Results of a Prospective Randomized Trial by Italian Lymphoma Foundation (FIL)

Blood (2011) 118 (21): 777.

https://doi.org/10.1182/blood.V118.21.777.777

Published: 2011

Journal Articles

Fludarabine and Mitoxantrone Followed by Yttrium-90 Ibritumumab Tiuxetan in Untreated Patients with Follicular Lymphoma. Long Term Efficacy and Toxicity Results of the FLUMIZ Trial.

Pier Luigi Zinzani, MD, PhD, Enrico Derenzini, MD, Cinzia Pellegrini, Luigi Rigacci, Alberto Fabbri, Federica Quirini, Vittorio Stefoni, Letizia Gandolfi, Lisa Argnani, Beatrice Casadei, Alessandro Broccoli, Alessandro Pulsoni, MD, Marco Gobbi, MD, Alessio Perrotti, Alfonso Zaccaria, Maria Teresa Voso, MD, Maria Giuseppina Cabras, Amalia De Renzo, Michele Baccarani, MD

Blood (2011) 118 (21): 1604.

https://doi.org/10.1182/blood.V118.21.1604.1604

Published: 2011

Journal Articles

Rituximab (R) Maintenance Versus Observation After Short Term Chemoimmunotherapy R-FND as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Updated Results and Safety of the Maintenance of An Intergruppo Italiano Linfomi (IIL) Randomized Trial.

Blood (2009) 114 (22): 1706.

https://doi.org/10.1182/blood.V114.22.1706.1706

Published: 2009

Journal Articles

A Phase II Trial of R-FM (Rituximab, Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan ( 90 Y-IT) for Untreated Follicular Lymphoma (FL) Patients.

Pier Luigi Zinzani, Monica Tani, Alessandro Broccoli, Enrico Derenzini, Alessandro Pulsoni, Amalia De Renzo, Stefano Fanti, Mariapaola Fina, Letizia Gandolfi, Cinzia Pellegrini, Vittorio Stefoni, Michele Baccarani

Blood (2009) 114 (22): 3743.

https://doi.org/10.1182/blood.V114.22.3743.3743

Published: 2009

Journal Articles

A Case-Control Study on the Role of an Antiviral Treatment with Interferon and Ribavirin after Conventional Chemotherapy in Diffuse Large B-Cell Lymphomas with Hepatitis C Virus (HCV) Infection

Roberto Guariglia, Stefano Luminari, Amalia De Renzo, Emilio Iannitto, Matteo Dell’Olio, Samantha Pozzi, Teresa Pierri, Lucia D’Amato, Antonio Traficante, Stefano Sacchi, Pellegrino Musto

Blood (2008) 112 (11): 3054.

https://doi.org/10.1182/blood.V112.11.3054.3054

Published: 2008

Journal Articles

Brief Chemoimmunotherapy Rituximab (R)-FND ± R Maintenance as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Preliminary Analysis of a Prospective Randomized IIL Trial

Blood (2008) 112 (11): 834.

https://doi.org/10.1182/blood.V112.11.834.834

Published: 2008

Journal Articles

Front-Line Brief Chemo-Immunotherapy Rituximab (R)-FND + Rituximab Consolidation ± Rituximab Maintenance in Elderly Patients with Untreated Advanced Stage Follicular Lymphoma (FL): First Interim Analysis of a Prospective Randomized Study (ML17638)

Blood (2007) 110 (11): 1278.

https://doi.org/10.1182/blood.V110.11.1278.1278

Published: 2007

Journal Articles

Diffuse Large B-Cell Lymphomas (DLBCL) with Hepatitis-C Virus (HCV) Infection: Incidence, Clinical Outcome and Preliminary Results of Antiviral Treatments (AVT) after Chemotherapy.

Blood (2006) 108 (11): 2442.

https://doi.org/10.1182/blood.V108.11.2442.2442

Published: 2006

Journal Articles

A Phase II Trial of FM (Oral Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) for Previously Untreated Follicular Lymphoma (FL) Patients.

Pier Luigi Zinzani, MD, PhD, Alessandro Pulsoni, MD, Manuela Balocco, MD, Monica Tani, MD, Stefano Fanti, MD, Alessio Perrotti, MD, Paolo Castellucci, MD, Francesco Zaja, MD, Alberto Fabbri, MD, Alfonso Zaccaria, MD, Maria Teresa Voso, MD, Pierpaolo Fattori, MD, Luciano Guardigni, MD, Patrizia Gentilini, MD, Maria Giuseppina Cabras, MD, Amalia De Renzo, MD, Luigi Rigacci, MD

Blood (2006) 108 (11): 2479.

https://doi.org/10.1182/blood.V108.11.2479.2479

Published: 2006

Journal Articles

Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study

Alfonso Mele, Alessandro Pulsoni, Elvira Bianco, Pellegrino Musto, Andrè Szklo, Maria Grazia Sanpaolo, Emilio Iannitto, Amalia De Renzo, Bruno Martino, Vincenzo Liso, Cristina Andrizzi, Simona Pusterla, Fausto Dore, Maddalena Maresca, Maria Rapicetta, Fabrizio Marcucci, Franco Mandelli, Silvia Franceschi

Blood (2003) 102 (3): 996–999.

https://doi.org/10.1182/blood-2002-10-3230

Published: 2003

Journal Articles

Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus–infected patients treated for non-Hodgkin lymphoma

Marcello Persico, Fedele De Marino, Giovanni Di Giacomo Russo, Alessandro Severino, Bruno Palmentieri, Marco Picardi, Aristide Morante, Bruno Rotoli, Roberto Torella, Amalia De Renzo

Blood (2002) 99 (2): 724–725.

https://doi.org/10.1182/blood.V99.2.724

Published: 2002

Journal Articles

Elderly Aggressive-Histology Non-Hodgkin’s Lymphoma: First-Line VNCOP-B Regimen Experience on 350 Patients

Blood (1999) 94 (1): 33–38.

https://doi.org/10.1182/blood.V94.1.33.413k08_33_38

Published: 1999

Journal Articles

Anaplastic Large Cell Lymphoma Hodgkin's-Like: A Randomized Trial of ABVD Versus MACOP-B With and Without Radiation Therapy

Blood (1998) 92 (3): 790–794.

https://doi.org/10.1182/blood.V92.3.790

Published: 1998

NARROW

Italian Real Life Experience with Brentuximab Vedotin: Results of a National Observational Study on Relapsed/Refractory Hodgkin's Lymphoma

Italian Real Life Experience with Brentuximab Vedotin: Results of a National Observational Study on Relapsed/Refractory Anaplastic Large Cell Lymphoma

The Combination of Weekly Infusion of Rituximab and Bortezomib Is Effective in Relapsed or Refractory Indolent and Mantle Cell Lymphoma: Long-Term Results of Phase II BRIL06 Study of the Fondazione Italiana Linfomi (FIL)

High Cure Rates of the Short-Term GITIL Chemotherapy Programme for Adult Patients with Burkitt Lymphoma

Role Of Interim,-PET In Poor Prognosis Young Patients With Diffuse Large B Cell Lymphoma At Diagnosis: Data From An Ancillary Study Of a Prospective Randomized Phase III Study (DLCL04) From the Fondazione Italiana Linfomi

Brief Chemoimmunotherapy R-FND with Rituximab Consolidation Followed by Randomization Between Rituximab Maintenance Vs. Observation As First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Final Results of a Prospective Randomized Trial by Italian Lymphoma Foundation (FIL)

Fludarabine and Mitoxantrone Followed by Yttrium-90 Ibritumumab Tiuxetan in Untreated Patients with Follicular Lymphoma. Long Term Efficacy and Toxicity Results of the FLUMIZ Trial.

Rituximab (R) Maintenance Versus Observation After Short Term Chemoimmunotherapy R-FND as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Updated Results and Safety of the Maintenance of An Intergruppo Italiano Linfomi (IIL) Randomized Trial.

A Phase II Trial of R-FM (Rituximab, Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan ( 90 Y-IT) for Untreated Follicular Lymphoma (FL) Patients.

A Case-Control Study on the Role of an Antiviral Treatment with Interferon and Ribavirin after Conventional Chemotherapy in Diffuse Large B-Cell Lymphomas with Hepatitis C Virus (HCV) Infection

Brief Chemoimmunotherapy Rituximab (R)-FND ± R Maintenance as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Preliminary Analysis of a Prospective Randomized IIL Trial

Front-Line Brief Chemo-Immunotherapy Rituximab (R)-FND + Rituximab Consolidation ± Rituximab Maintenance in Elderly Patients with Untreated Advanced Stage Follicular Lymphoma (FL): First Interim Analysis of a Prospective Randomized Study (ML17638)

Diffuse Large B-Cell Lymphomas (DLBCL) with Hepatitis-C Virus (HCV) Infection: Incidence, Clinical Outcome and Preliminary Results of Antiviral Treatments (AVT) after Chemotherapy.

A Phase II Trial of FM (Oral Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) for Previously Untreated Follicular Lymphoma (FL) Patients.

Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study

Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus–infected patients treated for non-Hodgkin lymphoma

Elderly Aggressive-Histology Non-Hodgkin’s Lymphoma: First-Line VNCOP-B Regimen Experience on 350 Patients

Anaplastic Large Cell Lymphoma Hodgkin's-Like: A Randomized Trial of ABVD Versus MACOP-B With and Without Radiation Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only